TNF and asthma: A trial that tested the efficacy of golimumab, a monoclonal antibody that targets TNF-α, in a large population of patients with uncontrolled severe asthma failed to demonstrate significant changes in lung function or reductions in severe exacerbations through week 24 of treatment compared to the placebo.